Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Barratt

Showing results (111-120 of 272) with videos related to

Pageof 28
Sort By:
Journal of the American Society of Nephrology : JASN|March 3, 2006
O-glycosylation of serum IgD in IgA nephropathyAlice C Smith, Jacob F de Wolff, Karen Molyneux, et al.
Journal of the American Society of Nephrology : JASN|January 15, 2024
Bridging the 13-Year Evidence Gap: A Time for Age-Inclusive ResearchLouise Oni, Rona Smith, Alan D Salama, et al.
NPJ Systems Biology and Applications|November 16, 2019
From expression footprints to causal pathways: contextualizing large signaling networks with CARNIVALAnika Liu, Panuwat Trairatphisan, Enio Gjerga, et al.
The Science of the Total Environment|February 27, 2026
Deep learning the droughts: Spatiotemporal monitoring of protracted dry conditions in Queensland, AustraliaCharles Joseph, Qingxia Jenny Wang, Shahbaz Mushtaq, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 11, 2022
Erratum to: Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: A Phase 3, randomised, open-label, active-controlled study (DOLOMITES)Jonathan Barratt, Branislav Andric, Avtandil Tataradze, et al.
Plos One|December 9, 2016
Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA NephropathyMin Jeong Kim, Stefan Schaub, Karen Molyneux, et al.
Advances in Therapy|September 19, 2021
Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES)Botond Csiky, Michael Schömig, Ciro Esposito, et al.
Nature Reviews. Nephrology|September 4, 2024
The pathogenesis of IgA nephropathy and implications for treatmentChee Kay Cheung, Suceena Alexander, Heather N Reich, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 28, 2026
KDIGO 2026 clinical practice guideline for Anemia in Chronic Kidney Disease (CKD): a commentary from the European Renal Best Practice (ERBP)Lucia Del Vecchio, Aleix Cases, Michele F Eisenga, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 2, 2021
Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES)Jonathan Barratt, Branislav Andric, Avtandil Tataradze, et al.
Pageof 28

Showing results (111-120 of 272) with videos related to

Sort By:
Pageof 28
Journal of the American Society of Nephrology : JASN|March 3, 2006
O-glycosylation of serum IgD in IgA nephropathyAlice C Smith, Jacob F de Wolff, Karen Molyneux, et al.
Journal of the American Society of Nephrology : JASN|January 15, 2024
Bridging the 13-Year Evidence Gap: A Time for Age-Inclusive ResearchLouise Oni, Rona Smith, Alan D Salama, et al.
NPJ Systems Biology and Applications|November 16, 2019
From expression footprints to causal pathways: contextualizing large signaling networks with CARNIVALAnika Liu, Panuwat Trairatphisan, Enio Gjerga, et al.
The Science of the Total Environment|February 27, 2026
Deep learning the droughts: Spatiotemporal monitoring of protracted dry conditions in Queensland, AustraliaCharles Joseph, Qingxia Jenny Wang, Shahbaz Mushtaq, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 11, 2022
Erratum to: Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: A Phase 3, randomised, open-label, active-controlled study (DOLOMITES)Jonathan Barratt, Branislav Andric, Avtandil Tataradze, et al.
Plos One|December 9, 2016
Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA NephropathyMin Jeong Kim, Stefan Schaub, Karen Molyneux, et al.
Advances in Therapy|September 19, 2021
Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES)Botond Csiky, Michael Schömig, Ciro Esposito, et al.
Nature Reviews. Nephrology|September 4, 2024
The pathogenesis of IgA nephropathy and implications for treatmentChee Kay Cheung, Suceena Alexander, Heather N Reich, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 28, 2026
KDIGO 2026 clinical practice guideline for Anemia in Chronic Kidney Disease (CKD): a commentary from the European Renal Best Practice (ERBP)Lucia Del Vecchio, Aleix Cases, Michele F Eisenga, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 2, 2021
Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES)Jonathan Barratt, Branislav Andric, Avtandil Tataradze, et al.
Pageof 28